
    
      PRIMARY OBJECTIVES:

      I. To collect long term safety and tolerability data in patients with myelofibrosis
      previously treated with ruxolitinib on protocol 2007-0169.

      OUTLINE:

      Patients continue to receive ruxolitinib orally (PO) once daily (QD) or twice daily (BID).
      Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
      Patients undergo follow-up assessment for safety over 10 minutes every 3 cycles.
    
  